Mendoza LLD, López VJL, Tamariz HE, De la Torre RFE, Barriga AF, Amador PC

Language: Spanish
References: 13
Page:
PDF size: 210.55 Kb.

ABSTRACT

Infection with human papillomavirus (HPV) infection is the most common worldwide sexually transmitted with a prevalence of 2.0 to 44.0%, the persistence of high-risk virus (HR-HPV) is a determining factor in the development of cervical cancer. In pregnant women the prevalence is 5-68%.
Objective: To determine the prevalence of genotypes of human papillomavirus high risk in pregnant patients at the Regional Hospital "Lic. Adolfo López Mateos " ISSSTE.
Material and Methods: We performed a transversal, observational and descriptive study which included 61 pregnant patients who presented to the hospital obstetrics. To which were performed cervical cytology, colposcopy and genotyping of human papillomavirus high risk. PCR samples were processed with the Cobas 4800 system.
Results: Of the 61 patients studied, 18 (29.51%) were positive pregnant Virus High Risk Human Papillomavirus (HRHPV) corresponding to a prevalence of 29.50%. 2 patients (11%) were HPV-16 and 16 patients (89%) the panel or "pool" of other high-risk virus containing genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The average age of the patients positive for HR-HPV was 26.4 years. The 55.5% of the HR-HPV positive patients were in the first quarter of gestation. Of the 61 patients included in the study, 9 patients (14.75%) had abnormal cytology and of these 7 were positive for HR-HPV (78%).
Conclusion: HR-HPV prevalence in pregnant women is high. The most prevalent genotype in our population is the subgroup ("pool") of 12 genotypes which are associated with a lower risk of cervical cancer with respect to types 16 and 18. It is necessary to encourage timely detection during pregnancy because it is a great opportunity to detect it early alteration.

REFERENCES

1. Diaz ML. Human papilloma virus: prevention and treatment. Obstet Gynecol Clin N Am 2008; 35: 199- 217.

2. Tatti S. Colposcopia y patología del tracto genital inferior. Panamericana. Argentina. 2008, pp 57-87, 284-288.

3. Domza G, Gudleviciene Z, Povilas K et al. Human papillomavirus infection in pregnant women. Arch Gynecol Obstet 2010; 284: 1105 – 1112.

4. Apgar B, Brotzman, Spitzer M. Colposcopía principios y práctica. ElsevierMasson. España 2ª Ed. 2009, pp: 21-34, 79 -100, 411-436.

5. Lizano M, Carrillo A, Contreras A. Infección por virus del Papiloma Humano: Epidemiología, historia natural y carcinogénesis. Cancerología 2009; 4: 205-216.

6. Bandyopadhyay S, Chatterje R. HPV viral load determination during pregnancy as a possible cervical cancer risk. J. Exp. Clin. Cancer Res 2006; 25: 29-38.

7. Hernández C, Smith J et al. Prevalencia de infección por virus de papiloma humano (VPH) de alto riesgo y factores asociados en embarazadas derechohabientes del IMSS en el estado de Morelos. Salud Pública Mex 2005;47: 423 -429.

8. Fader A, Alward E Chirico C et al. Cervical dysplasia in pregnancy: a multi – institutional evaluation.

9. Smith E, Ritchie J, Yankowitz J et al. HPV prevalence and concordance in the cervix and oral cavity of pregnant women. Infect Dis Obstet Gynecol 2004;12: 45-56.

10. Doman G. Human papillomavirus infection in pregnant women. Arch Gynecol Obstet 2011; 284: 1105 -1112.

11. Aydin Y. Prevalence of human papilloma virus infection in pregnant Turkish women compared with non-pregnant women. Eur J Gynecol Oncol 2010;31(1):72-74.

12. Castle P, Stoler M, Wright T et al. Perfomance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV 18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

13. Literature review current through: Mar 2012. | This topic last updated: mar 13, 2012. http://www.uptodate.com.pbidi.unam.mx:8080.